So, with the slightly-surprising performance of Victrelis in the Hep C space (slowly catching up with Vertex's Incivek), it makes sense for New Merck to try to monetize some of the second fiddles Schering-Plough held, in the next-gen Hep C space. Yesterday, New Merck did just that -- and avoided additional R&D cash burn to boot.
From the Microbiotix press release, then:
. . . .Microbiotix gains worldwide rights to develop, manufacture and commercialize MBX-700 and MBX-701 (formerly SCH 900942 and SCH 900188), two non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. MBX-700 is in Phase I clinical testing and MBX-701 is currently in preclinical development.This is a smart move for New Merck -- as it already has several more promising on-market, and in-trials candidates, underway in the Hep C space.
Merck is eligible for milestone payments during development stages of the candidates, and for royalty payments from any resulting products. Specific terms of the agreement were not disclosed. MBX-700 and MBX-701 are designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase, a clinically validated target that is essential for viral genome replication. In vitro studies have shown MBX-700 to be among the most potent HCV NS5B polymerase inhibitors. . . .
And, if Whitehouse Station turns out to be wrong about these legacy Schering-Plough polymerase inhibitors (for Hep C inhibition), New Merck will still get a share of the revenue, while having avoided perhaps $100 million in cash research, development and clinical trials costs -- to find out what they actually can do.
This sort of deal is exactly what Mr. Frazier meant -- speaking at Goldman Sachs yesterday -- would be his signature: thoughtful in- and out-licensing. Well-played, sir.
No comments:
Post a Comment